Feasibility of <i>BRCA1/2</i> Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series

Feasibility of <i>BRCA1/2</i> Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, with most patients diagnosed at advanced stages. First-line treatment based on a combined chemotherapy (FOLFIRINOX or gemcitabine plus nab-paclitaxel) provides limited benefits. Olaparib, a PARP inhibitor, has been approved as maintena...

Full description

Bibliographic Details
Main Authors: Rossella Bruno, Elisa Sensi, Cristiana Lupi, Mirella Giordano, Laura Bernardini, Caterina Vivaldi, Lorenzo Fornaro, Enrico Vasile, Daniela Campani, Gabriella Fontanini
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Diagnostics
Subjects:
pancreatic cancer
next generation sequencing
<i>BRCA1/2</i>
PARP inhibitors
Online Access:https://www.mdpi.com/2075-4418/11/6/1046

Internet

https://www.mdpi.com/2075-4418/11/6/1046

Similar Items